eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
30 hedge funds and large institutions have $10.4M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 1 closing their positions.
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
11% more funds holding
Funds holding: 27 → 30 (+3)
24% less capital invested
Capital invested by funds: $13.6M → $10.4M (-$3.22M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IDA
Intelligence Driven Advisers
Carlsbad,
California
|
+$24.8K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$17.1K |
| 3 |
Renaissance Technologies
New York
|
+$12.4K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.94K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$9K |
| 2 |
WFAG
Wescott Financial Advisory Group
Philadelphia,
Pennsylvania
|
-$7.61K |
| 3 |
Two Sigma Investments
New York
|
-$4.39K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Simplex Trading
Chicago,
Illinois
| $3K | +$1.48K | +117 | +52% |
|
27
Morgan Stanley
New York
| $2.57K | – | – | – |
|
28
Osaic Holdings
Scottsdale,
Arizona
| $1K | – | – | – |
|
29
Wells Fargo
San Francisco,
California
| $32 | – | – | – |
|
30
Bank of America
Charlotte,
North Carolina
| $20 | +$25 | +2 | New |
|
|
TSS
31
Two Sigma Securities
New York
| – | -$9K | -648 | Closed |
|
EFTR Hedge Fund Activity: Q4 2022 in Review
30 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q4 2022, worth a combined $10.4M — down 24% from $13.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new EFTR positions and 1 closed out — a net gain of 3 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Intelligence Driven Advisers, opening a new position worth an estimated $24.8K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $9K sold.
- 30 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q4 2022, up from 27 in Q3 2022.
- Funds reported $10.4M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q4 2022, down 24% quarter-over-quarter.
- 4 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q4 2022 and 1 closed out, a net change of +3 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q4 2022 was Intelligence Driven Advisers, an estimated $24.8K added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q4 2022 was Two Sigma Securities, an estimated $9K sold.
Based on aggregated 13F filings for Q4 2022.